Pitt County Memorial Hospital
- Type
- Teaching hospital
- Where
- GREENVILLE, NC
- Medicare CCN
- 340040
- Received
- $685,994 in 69 records, 2020 ($471,841 general, $214,153 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Pitt County Memorial Hospital, Incorporated Fuzzy (name and state)
- Business registration: PITT COUNTY MEMORIAL HOSPITAL, INCORPORATED Fuzzy (name and state)
- Nonprofit contractor: Pitt County Memorial Hospital Fuzzy (name and state)
- Federal award recipient: PITT COUNTY MEMORIAL HOSPITAL, INCORPORATED Fuzzy (name and state)
- Nonprofit: PITT COUNTY MEMORIAL HOSPITAL INC Fuzzy (name and state)
- Trademark owner: Pitt County Memorial Hospital, Incorporated Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 25 | $471,841 |
| 2020 | Research payment | 44 | $214,153 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Olympus America Inc. | 1 | $440,391 | 2020 |
| PFIZER INC. | 2 | $69,595 | 2020 |
| SEAGEN INC. | 3 | $57,435 | 2020 |
| Novartis Pharmaceuticals Corporation | 2 | $20,475 | 2020 |
| Abbott Laboratories | 5 | $17,409 | 2020 |
| ZOLL Circulation Inc | 4 | $16,041 | 2020 |
| Becton, Dickinson and Company | 11 | $11,285 | 2020 |
| Vifor (International) Ltd. | 4 | $11,275 | 2020 |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | 1 | $11,260 | 2020 |
| Janssen Research & Development, LLC | 1 | $9,715 | 2020 |
| AstraZeneca Pharmaceuticals LP | 1 | $6,098 | 2020 |
| Penumbra, Inc. | 1 | $6,000 | 2020 |
| Biogen, Inc. | 1 | $3,373 | 2020 |
| Daiichi Sankyo Inc. | 23 | $1,613 | 2020 |
| Linvatec Corporation | 1 | $1,299 | 2020 |
| ACELL, INC. | 2 | $924 | 2020 |
| Merck Sharp & Dohme LLC | 1 | $652 | 2020 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $500 | 2020 |
| Bio-Rad Laboratories, Inc. | 2 | $362 | 2020 |
| GenMark Diagnostics, Inc. | 2 | $285 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Education | 3 | $441,316 |
| Research payment | 44 | $214,153 |
| Gift | 6 | $16,404 |
| Charitable Contribution | 11 | $11,285 |
| Grant | 1 | $1,299 |
| Space rental or facility fees (teaching hospital only) | 2 | $1,250 |
| Food and Beverage | 2 | $285 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Linvatec Corporation | $1,299 | Grant | In-kind items and services | MICROFREE Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-12-14 | Merck Sharp & Dohme LLC | $652 | Research payment | In-kind items and services | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2020 |
| 2020-11-11 | Abbott Laboratories | $1,410 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-11-10 | Abbott Laboratories | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Mitra Clip system Device, Vascular | 2020 | |
| 2020-10-26 | SEAGEN INC. | $28,490 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-10-26 | SEAGEN INC. | $19,448 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-10-26 | SEAGEN INC. | $9,496 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-10-08 | Daiichi Sankyo Inc. | $44 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-10-08 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-10-08 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-10-08 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-09-24 | Becton, Dickinson and Company | $1,536 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-09-24 | Becton, Dickinson and Company | $680 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-09-21 | Becton, Dickinson and Company | $1,536 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-09-21 | Becton, Dickinson and Company | $680 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-09-11 | Becton, Dickinson and Company | $1,536 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-09-11 | Becton, Dickinson and Company | $680 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-09-08 | AstraZeneca Pharmaceuticals LP | $6,098 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2020 |
| 2020-09-08 | Daiichi Sankyo Inc. | $25 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-09-05 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $11,260 | Research payment | Cash or cash equivalent | A STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY , PHARMACOKINETICS OF SINGLE ASCENDING DOSE OF MT-3921 IN SUBJECTS WITH | 2020 | |
| 2020-09-02 | Becton, Dickinson and Company | $1,536 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-09-02 | Becton, Dickinson and Company | $680 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-08-28 | Becton, Dickinson and Company | $680 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-08-26 | Becton, Dickinson and Company | $1,536 | Charitable Contribution | In-kind items and services | BD MAX Device, Molecular Diagnostics | 2020 | |
| 2020-08-17 | Janssen Research & Development, LLC | $9,715 | Research payment | Cash or cash equivalent | Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, | 2020 | |
| 2020-08-14 | Bio-Rad Laboratories, Inc. | $250 | Gift | In-kind items and services | Seraclone Device, Blood Typing | 2020 | |
| 2020-08-14 | Bio-Rad Laboratories, Inc. | $111 | Gift | In-kind items and services | Seraclone Device, Blood Typing | 2020 | |
| 2020-08-12 | Abbott Laboratories | $104 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-07-29 | Novartis Pharmaceuticals Corporation | $10,299 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) | 2020 |
| 2020-07-22 | Penumbra, Inc. | $6,000 | Research payment | Cash or cash equivalent | Penumbra SMART Coil Device, Neurointervention | SURF | 2020 |
| 2020-07-20 | Vifor (International) Ltd. | $2,275 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | DIAMOND PAT-CR-302 | 2020 |
| 2020-07-20 | Vifor (International) Ltd. | $250 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | DIAMOND PAT-CR-302 | 2020 |
| 2020-07-20 | Vifor (International) Ltd. | $250 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | DIAMOND PAT-CR-302 | 2020 |
| 2020-07-14 | Biogen, Inc. | $3,373 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion | 2020 | |
| 2020-06-08 | Becton, Dickinson and Company | $200 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-06-08 | GenMark Diagnostics, Inc. | $84 | Food and Beverage | In-kind items and services | ePlex Device, Devices | 2020 | |
| 2020-05-24 | Olympus America Inc. | $440,391 | Education | In-kind items and services | 3-D Videoscopes Device, Surgical Endoscopy | 2020 | |
| 2020-05-20 | Novartis Pharmaceuticals Corporation | $10,176 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | OBSERVATIONAL REGISTRY OF TREATMENT PATTERNS IN US HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION | 2020 |
| 2020-05-08 | Daiichi Sankyo Inc. | $35 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-05-08 | Daiichi Sankyo Inc. | $35 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-05-08 | Daiichi Sankyo Inc. | $22 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-05-06 | Abbott Laboratories | $9,145 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-04-21 | GenMark Diagnostics, Inc. | $201 | Food and Beverage | In-kind items and services | ePlex Device, Devices | 2020 | |
| 2020-03-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-02-19 | PFIZER INC. | $52,196 | Research payment | In-kind items and services | MYLOTARG Biological, ONCOLOGY | A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT | 2020 |
| 2020-02-19 | PFIZER INC. | $17,398 | Research payment | In-kind items and services | MYLOTARG Biological, ONCOLOGY | A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT | 2020 |
| 2020-02-19 | Abbott Laboratories | $5,999 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-02-17 | ACELL, INC. | $592 | Education | Cash or cash equivalent | 2020 | ||
| 2020-02-17 | ACELL, INC. | $332 | Education | Cash or cash equivalent | 2020 | ||
| 2020-02-10 | Daiichi Sankyo Inc. | $22 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-02-10 | Daiichi Sankyo Inc. | $22 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-02-10 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-02-10 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-02-10 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-02-10 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-02-10 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-02-10 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-01-20 | Vifor (International) Ltd. | $8,500 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | DIAMOND PAT-CR-302 | 2020 |
| 2020-01-09 | Daiichi Sankyo Inc. | $864 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-01-09 | Daiichi Sankyo Inc. | $288 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-01-09 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-01-09 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-01-09 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-01-09 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-01-09 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176b-C-U313 | 2020 |
| 2020-01-01 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2020 | |
| 2020-01-01 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2020 | |
| 2020-01-01 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2020 | |
| 2020-01-01 | ZOLL Circulation Inc | $4,010 | Gift | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Greenville, NC, county Pitt County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Greenville, NC | County Pitt County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 92,857 | 177,193 | 10,730,404 |
| Population, 2020 census P1 | 87,521 | 170,243 | 10,439,388 |
| Median age B01002 | 27.3 | 33.0 | 39.1 |
| Under 18 B01001 | 18.8% | 21.0% | 21.8% |
| 65 and over B01001 | 11.1% | 14.5% | 17.2% |
| Households B11001 | 40,783 | 74,533 | 4,282,345 |
| Foreign born B05002 | 5.0% | 5.8% | 9.1% |
| Median household income B19013 | $49,748 | $58,188 | $72,388 |
| Median family income B19113 | $74,840 | $80,889 | $90,290 |
| Per capita income B19301 | $33,924 | $34,160 | $41,385 |
| Poverty rate B17001 | 24.6% | 19.8% | 13.0% |
| Unemployment rate B23025 | 9.0% | 7.8% | 4.7% |
| Civilian labor force B23025 | 49,091 | 89,984 | 5,336,863 |
| Mean commute (minutes) B08013 | 18.8 | 22.1 | 25.1 |
| Bachelor's degree or higher B15003 | 39.1% | 33.8% | 35.7% |
| Housing units B25001 | 45,767 | 82,638 | 4,895,668 |
| Owner-occupied B25003 | 32.7% | 51.4% | 66.6% |
| Renters B25003 | 67.3% | 48.6% | 33.4% |
| Median home value B25077 | $233,500 | $208,900 | $288,900 |
| Median gross rent B25064 | $1,007 | $993 | $1,228 |
| White, not Hispanic B03002 | 48.5% | 51.9% | 60.0% |
| Black B03002 | 39.5% | 34.7% | 20.0% |
| Hispanic or Latino B03002 | 5.5% | 7.9% | 11.3% |
| Asian B03002 | 2.7% | 2.0% | 3.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greenville, NC.
Comments